A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (ALTAIR)
The ALTAIR study is a research trial for people with advanced or metastatic non-small cell lung cancer. Researchers are testing new combinations of existing medicines (Cyramza) with a new medicine called Rilvegostomig. The study has two main parts: Part A focuses on finding a safe dose and understanding potential side effects of these new combinations. Part B then looks at how well these treatments work in a larger group of people. Doctors will be carefully monitoring participants' health, including any side effects, to make sure the treatments are as safe and effective as possible.
At a glance
What is this study about?
The ALTAIR study is a clinical trial exploring new treatment options for people with advanced or metastatic non-small cell lung cancer. This type of cancer has spread to other parts of the body. The study is particularly interested in combining an existing medicine called Cyramza with a new experimental drug called Rilvegostomig. These new combinations are being tested to see if they can be more effective than current treatments.
The study is divided into two main stages. The first stage, called Part A, is a 'safety run-in'. During this stage, a small group of participants will receive different doses of the new medicine combinations. The main goal here is to carefully watch for any side effects and determine the safest and most effective dose to use in the later stages. Doctors will check many things like blood tests, heart readings (ECGs), and overall health to make sure the treatment is well-tolerated.
Once a safe dose is found, the study moves to Part B, which is called 'dose expansion'. In this stage, more participants will receive the chosen dose. Here, the research team will continue to monitor safety but will also pay close attention to how well the treatment is working. They will look at whether the treatment shrinks the cancer or stops it from growing, and how long these effects last. The aim is to find out if these new combinations could be a promising future treatment for this type of lung cancer.
Key takeaways
- This study is for advanced or metastatic non-small cell lung cancer.
- It's testing new combinations of medicines (Cyramza + Rilvegostomig).
- The first stage focuses on finding a safe dose and checking for side effects.
- The second stage checks how effective the treatment is against the cancer.
- Participation involves regular clinic visits, infusions, and health checks.
Who may be eligible?
To be considered for this study, you must be an adult aged 18 years or older, as the study is not designed for younger individuals. The study is open to both men and women.
Crucially, you must have advanced or metastatic non-small cell lung cancer. This means your lung cancer has spread beyond its original location. The study will have specific medical criteria that your doctor will check to ensure it's suitable for you to take part.
If you meet these general requirements, your doctor can then discuss the more detailed medical checks to see if this study is a good fit for your individual situation.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have advanced or metastatic non-small cell lung cancer?
- Are you able to attend regular clinic appointments for treatment and check-ups?
- Are you willing to follow the study's treatment schedule and tests?
What does participation involve?
If you join the ALTAIR study, you would receive the study medication, which involves a combination of Cyramza and Rilvegostomig, given as an infusion into a vein. This would happen at regular visits to the clinic.
Throughout the study, you would have frequent check-ups, which include physical examinations, blood tests, heart rhythm checks (ECGs), and monitoring of your vital signs like blood pressure and pulse. These are important for checking your health and how the treatment is affecting you. The doctors will also regularly assess whether the treatment is helping your cancer, typically through scans.
The total length of your participation would depend on how your body responds to the treatment and the study's design. You would have regular contact with the study team, and they would explain your schedule in detail before you decide to take part.
Potential risks and benefits
Locations (7)
- —UnverifiedGermany
- —UnverifiedSpain
- —UnverifiedFrance
- —UnverifiedPoland
- —UnverifiedBelgium
- —UnverifiedNetherlands
- —UnverifiedItaly
Common questions
What type of cancer is this study for?
This study is for people with advanced or metastatic non-small cell lung cancer, meaning the cancer has spread.
What medicines are being tested?
The study is testing combinations of an existing medicine called Cyramza with a new medicine called Rilvegostomig.
What is the main goal of the first part of the study?
The first part aims to find a safe dose and understand the potential side effects of the new treatment combinations.
Will I know if the treatment is working?
The study team will regularly assess your cancer through scans and other tests to see how the treatment is affecting it.
Can I leave the study at any time?
Yes, you have the right to withdraw from the study at any point, and your decision will not affect your medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.